Strategies for treating HIV-related lipodystrophy

Area of Science:

• Infectious Diseases
• Endocrinology
• Public Health

Background:

• HIV infection is now a chronic disease, leading to prevalent complications like lipodystrophy.
• HIV-related lipodystrophy significantly impacts patient quality of life and increases cardiovascular risk.
• The aetiopathogenesis, diagnosis, prevention, and therapy of lipodystrophy remain largely unexplored.

Purpose of the Study:

• To review the current understanding of HIV-related lipodystrophy.
• To discuss the multifactorial aetiology, diagnostic challenges, and therapeutic options.
• To emphasize the need for an individualized management strategy.

Main Methods:

• Literature review of current evidence on HIV-related lipodystrophy.
• Analysis of contributing factors including HIV infection, antiretroviral therapy, and patient-related elements.
• Evaluation of various therapeutic strategies and their limitations.

Main Results:

• Lipodystrophy etiology is multifactorial, involving HIV, antiretroviral therapy, and patient factors.
• Diagnosis is hindered by the lack of a formal definition and co-existing wasting syndromes.
• Therapeutic approaches show limited success and require careful consideration of potential complications.

Conclusions:

• HIV-related lipodystrophy is a significant challenge in chronic HIV management.
• Current therapeutic options are limited, necessitating an individualized and judicious approach.
• Further research is crucial to understand and effectively manage lipodystrophy and its associated metabolic risks.